Macrodosing to microdosing with psychedelics: Clinical, social, and cultural perspectives
Transcultural Psychiatry August 29, 2022 DOI: 10.1177/13634615221119386 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Review Peer reviewed |
|---|---|
| Topics | LSD Psilocybin Microdosing |
| Keywords | Hallucinogen Context archaeology Cognition Intervention counseling Psychotherapist |
| Citations | 17 |
| Key findings | Microdosing is a nascent practice with potential therapeutic and enhancement benefits, but its effects remain mostly unexplored in formal research. |
Abstract
To date, the clinical and scientific literature has best documented the effects of classical psychedelics, such as lysergic acid diethylamide (LSD), psilocybin, and dimethyltryptamine (DMT), in typical quantities most often associated with macrodosing. More recently, however, microdosing with psychedelics has emerged as a social trend and nascent therapeutic intervention. This variation in psychedelic practice refers to repeat, intermittent ingestion of less-than-macrodose amounts that do not cause the effects associated with full-blown “trips”. Microdosing paves the road to incorporating psychedelic drugs into a daily routine while maintaining, or even improving, cognitive and mental function. Unlike macrodosing with psychedelics, the influence of microdosing remains mostly unexplored. And yet, despite the paucity of formal studies, many informal accounts propose that microdosing plays an important role as both a therapeutic intervention (e.g., in mental disorders) and enhancement tool (e.g., recreationally—to boost creativity, improve cognition, and drive personal growth). In response to this relatively new practice, we provide an integrative synthesis of the clinical, social, and cultural dimensions of microdosing. We describe some of the overarching context that explains why this practice is increasingly in vogue, unpack potential benefits and risks, and comment on sociocultural implications. In addition, this article considers the effects that macro- and microdoses have on behavior and psychopathology in light of their dosage characteristics and contexts of use.
In the evidence
This study is part of the evidence base for a synthesis in the library. Here is how each one recorded it.
-
Argues that microdosing is a nascent practice with potential therapeutic and enhancement benefits whose effects remain mostly unexplored in formal research.
Synthesized
Comparable studies
Other narrative reviews on LSD and microdosing, most cited first.
| Study | Year | Design | Participants |
|---|---|---|---|
| The risk of chronic psychedelic and MDMA microdosing for valvular heart disease | 2023 | Review | |
| Is microdosing a placebo? A rapid review of low-dose LSD and psilocybin research | 2024 | Rapid review | n = 19 |
| Side effects of microdosing lysergic acid diethylamide and psilocybin: A systematic review of potential physiological and psychiatric outcomes | 2025 | Review | |
| Microdosing Psychedelics to Restore Synaptic Density in Schizophrenia. | 2025 | Review | |
| Self-medication with psychedelics: a scoping review and narrative synthesis of review-level evidence Self-medicating individuals | 2026 | Scoping review |
Citations in the library
Cited by 15
- Culture, context, and ethics in the therapeutic use of hallucinogens: Psychedelics as active super-placebos? Transcultural Psychiatry October 1, 2022
- Microdosing psychedelics and the risk of cardiac fibrosis and valvulopathy: Comparison to known cardiotoxins Journal of Psychopharmacology January 12, 2024
- Microdosing with classical psychedelics: Research trajectories and practical considerations Transcultural Psychiatry October 1, 2022
- Regulatory Challenges of Integrating Psychedelics into Mental Health Sector Psychoactives April 22, 2025
- Exploring a Decade of Microdosing Research: A Qualitative Meta-synthesis of Microdosing Literature Deviant Behavior February 9, 2026
and 10 more in the library
Cites 72
- Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial Journal of Psychopharmacology November 30, 2016
- Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance Psychopharmacology July 7, 2006
- Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. The Lancet Psychiatry May 17, 2016
- Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer Archives of General Psychiatry September 7, 2010
- Human hallucinogen research: guidelines for safety. Journal of Psychopharmacology July 1, 2008
and 67 more in the library